Tariff talk hits pharma, luxury

Tariff policy is now hitting two very different businesses at once: imported brand-name drugs and European luxury goods sold into the United States. (whitehouse.gov) On April 2, the White House said it would impose tariffs of up to 100% on patented pharmaceutical products from companies that have not signed pricing deals with the administration. Companies that pledge to move production to the United States can cut that rate to 20%, and companies that also strike pricing agreements can avoid the tariff entirely. (whitehouse.gov) Markets treated that as a company-by-company risk, not a blanket sector rule. CNBC reported on April 2 that the policy applies to branded drugs with major exemptions, while STAT said many large drugmakers were spared because they had already negotiated manufacturing or pricing commitments. (cnbc.com) (statnews.com) The same tariff fight is hanging over European luxury groups because the United States has become one of their most important growth markets. CNBC reported in April 2025 that a White House pause reduced the European Union rate to 10% for 90 days, down from a planned 20%, but left the threat of higher duties in place if talks fail. (cnbc.com) That matters for luxury because the sector was already leaning on American demand while China stayed weak. Reuters-republished market reporting said brands such as LVMH, Hermès, Kering and Richemont had been counting on U.S. shoppers to offset softer sales in China before tariff fears and market volatility hit sentiment. (marketscreener.com) Luxury companies have fewer immediate policy carve-outs than drugmakers, but they do have a familiar tool: higher prices. Hermès said in April 2025 that it would raise U.S. prices from May 1 to “fully offset” the impact of the 10% tariff then in force. (cnbc.com) Drugmakers argue tariffs work differently in medicines than in handbags because supply chains are regulated and hard to move quickly. STAT reported that the administration’s order opened a route to lower tariffs through onshoring and pricing deals, while analysts told CNBC that exemptions meant the burden would fall unevenly across companies with more imported branded products. (statnews.com) (cnbc.com) Trade officials have framed the broader tariff push as a supply-chain and bargaining strategy. The United States Trade Representative says the administration’s 2026 tariff actions are aimed at rebalancing trade relationships, and the White House said the drug tariffs were meant to strengthen domestic production and press companies on prices. (ustr.gov) (whitehouse.gov) The immediate result is not one clean market story but two uneven ones. In pharmaceuticals, tariff exposure now depends on which companies signed Washington deals; in luxury, exposure depends on how much pricing power brands still have with U.S. shoppers if temporary levies become permanent. (cnbc.com) (marketscreener.com)